文献速递乳腺癌放疗

原发化疗后放疗(RAPCHEM):荷兰登记研究中的实践差异

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).
PubMed 文献 · Radiother Oncol · 2020-02-10

荷兰前瞻性队列研究(RAPCHEM,BOOG 2010-03)纳入848例cT1-2N1乳腺癌患者,接受原发系统治疗后手术并按基于共识的研究指南行术后放疗。结果显示64%患者按指南治疗,11%放疗范围小于预定靶区,25%大于指南推荐;中间风险组(ypN1)差异最大,仅54%符合指南。

要点

  • 原发化疗后术后放疗与共识指南的总体符合率为64%。
  • 中间风险组(ypN1)符合率最低,仅54%按指南治疗。
  • 25%患者接受了比指南更广泛的放疗,11%范围不足。

核心结论

  • 原发系统治疗后术后放疗存在对共识研究指南的显著偏离,中间风险患者尤为明显。

研究设计与样本

  • 荷兰前瞻性队列研究(RAPCHEM:NCT01279304,BOOG 2010-03),2011年1月至2015年1月纳入17家荷兰放疗中心的848例cT1-2N1乳腺癌患者。

主要发现

  • 低风险组(ypN0)292例,中间风险组(ypN1)374例,高风险组(ypN2)182例。
  • 64%患者按研究指南治疗,11%放疗范围小于预定靶区,25%放疗范围大于指南推荐。
  • 中间风险组仅54%按指南治疗,为差异最大的风险组。

关键数值与推荐

  • 研究指南推荐保乳治疗患者行全乳放疗。
  • ypN0(低风险):放疗乳房,乳房切除术后不放疗。
  • ypN1(中间风险):放疗乳房或胸壁。
  • ypN2(高风险):放疗乳房或胸壁,包括区域淋巴结。

临床怎么用

  • 原发化疗后术后放疗决策需关注风险分组,中间风险组(ypN1)偏离指南最常见。
  • 实际放疗范围与指南推荐存在差异,未来需结合危险因素和实际放疗评估结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a prospective cohort study in the Netherlands (RAPCHEM: NCT01279304, BOOG 2010-03) in breast cancer (BC) patients treated with primary systemic therapy (PST), followed by surgery and post-operative radiation therapy (RT) according to a predefined consensus-based study-guideline (SG). The aim of the current analysis is to evaluate adherence to the SG. METHODS: From January 2011 to January 2015, patients with cT1-2N1 BC treated in 17 Dutch RT Centres were included. Patients with four or more suspicious nodes at imaging were excluded. SG recommended whole breast RT for patients treated with breast conserving therapy. SG on loco(-regional) RT were defined for three risk groups based on the ypN status: (1) ypN0 (low-risk): RT breast and no RT after mastectomy; (2) ypN1 (intermediate-risk): RT breast or chest wall; (3) ypN2 (high-risk): RT breast or chest wall, including regional lymph nodes. RESULTS: We included 848 patients: 292 in the low-risk group; 374 in the intermediate-risk group; 182 in the high-risk group. Overall, 64% of the patients was treated according to the SG; 11% received less RT than the predefined target volumes and 25% received more extensive RT than according to the SG. The largest variation was seen in the intermediate risk group, where only 54% was treated according to the SG. CONCLUSION: Substantial deviation from the SG for post-operative RT was observed after PST, especially in patients with an intermediate-risk. Future analyses will evaluate outcome of these patients in relation to risk factors and the actual RT given.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Boersma LJ, Verloop J, Voogd AC, et al. Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). Radiother Oncol. 2020. PMID: 32058873. doi:10.1016/j.radonc.2020.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。